Published Nov 2003
Drummond M, Brown R, Fendrick AM, et al. Use of Pharmacoeconomics Information—report of the ISPOR Task Force on Use of Pharmacoeconomic/Health Economic Information in Health-Care Decision Making. Value Health. 2003;6(4):407-416.
Objectives: Despite the growing number of pharmacoeconomic
(PE)/health economic (HE) studies, very little is
known about their use by decision makers. The objectives
of the Task Force were to ensure that the good research
practices of PE/HE studies pay attention to the needs of
health-care decision makers and to develop a “toolbox”
for the health-care decision maker wanting to interpret
and use PE/HE studies.
Methods: The membership of the Task Force consisted of
individuals involved in making decisions about the availability
or use of medicines and researchers into the use of
economic evaluations. The group communicated by Email
and face-to-face meetings. A literature review of
decision makers’ attitudes toward PE/HE studies and
published economic evaluation guidelines was undertaken.
In addition, a focus group discussion was held with
opinion leaders in managed care pharmacy.
Results: The literature review identified 16 surveys of
decision makers’ attitudes toward PE/HE studies and 15
published guidelines that outlined reporting requirements
for economic evaluations. These were reviewed and classified.
Based on the published literature and comments
from decision makers, seven additional reporting requirements
for studies were specified.
Conclusions: While the Task Force’s additional reporting
requirements may be helpful to decision makers, they
raise a number of issues. These include the feasibility of
meeting the additional requirements, whether decision
makers should receive more education in economic evaluation,
and whether there should be more study of healthcare
decision-making procedures themselves.
Keywords: cost-effectiveness analysis, decision making, guidelines, implementation.